CPRS led graduate students to participate in the 8th China Pharmaceutical Regulatory Science Conference (2025) held in Beijing
The 8th China Pharmaceutical Regulatory Science Conference (2025), hosted by the China Society for Drug Regulation, was held in Beijing from June 13 to 15. The conference was themed "Comprehensive Deepening of Reform, Full Promotion of Innovation, Global High-quality Development - Empowering the Modernization ...
Opening ceremony for Advanced Training Programme for Mechanism and Quality of Chinese Medicine 2025 held at UM
The opening ceremony for the Advanced Training Programme for Mechanism and Quality of Chinese Medicine 2025 was held at the University of Macau (UM) on 27 May. The programme is jointly organised by the China Science and Technology Exchange Center (CSTEC) of the Ministry ...
Director Hu Yuanjia of CPRS was invited to attend the “2025 Pharmaceutical Innovation Policy Forum”
The "2025 Pharmaceutical Innovation Policy Forum", hosted by the China Pharmaceutical Innovation and Research Development Association (PhIRDA), co-organized by the Medicinal Policy Specialty Committee and the Innovation R&D Services Specialty Committee of PhIRDA, and supported by the Science and Technology Commission of Minhang District, ...
CPRS was invited to attend the “2025 DIA China Annual Meeting”
The "2025 DIA China Annual Meeting" was successfully held at the Zhangjiang Science Hall in Shanghai from May 22 to 25. The conference was themed "Gathering Global Wisdom to Lead Pharmaceutical Innovation," bringing together representatives of global drug regulatory agencies, scientific researchers and industry ...
UM, Pharmaceutical Administration Bureau sign cooperation agreements on third-party technical assessment of proprietary Chinese medicines and testing of Chinese medicine
The University of Macau (UM) and the Pharmaceutical Administration Bureau (ISAF) of the Macao SAR Government have signed a cooperation agreement on third-party technical assessment of proprietary Chinese medicines and a cooperation agreement on third-party testing of Chinese medicine. Under the agreements, both the ...